The Experts below are selected from a list of 792 Experts worldwide ranked by ideXlab platform
John F Hess - One of the best experts on this subject based on the ideXlab platform.
-
randomized controlled field trial to assess efficacy of a moraxella bovis pilin cytotoxin moraxella bovoculi cytotoxin subunit vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis
American Journal of Veterinary Research, 2012Co-Authors: John A. Angelos, Louise M. Ball, Khaled G Gohary, John F HessAbstract:Objective—To evaluate efficacy of a recombinant Moraxella bovis pilin-cytotoxin-Moraxella bovoculi cytotoxin subunit vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis (IBK). Animals—107 beef steers. Procedures—2 groups of calves were inoculated SC with an immunostimulating complex (ISCOM) matrix adjuvant (control group; n = 54) or a recombinant M bovis pilin-cytotoxin–M bovoculi cytotoxin subunit antigen with the ISCOM matrix adjuvant (vaccine group; 53); calves received booster injections 21 days later. Calves were examined once weekly for 16 weeks. Investigators and herd managers were not aware of the inoculum administered to each calf throughout the trial. Primary outcome of interest was the cumulative proportion of calves that developed IBK. Serum samples were obtained before inoculation (day 0) and on days 42 and 112. Serum hemolysin-neutralizing titers against native M bovis and M bovoculi cytotoxin were determined. Results—No difference was detected between groups for th...
-
prevention of naturally occurring infectious bovine keratoconjunctivitis with a recombinant moraxella bovis pilin moraxella bovis cytotoxin ISCOM matrix adjuvanted vaccine
Veterinary Microbiology, 2007Co-Authors: John A. Angelos, Robert G Bonifacio, Louise M. Ball, John F HessAbstract:Abstract To evaluate the efficacy of a recombinant Moraxella bovis pilin– M. bovis cytotoxin subunit vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis (IBK; pinkeye), a randomized, blinded, controlled field trial was conducted during summer 2005 in a northern California herd of beef cattle. One hundred and one steers were vaccinated with ISCOM matrix (adjuvant control), recombinant M. bovis cytotoxin carboxy terminus + ISCOM matrix (MbxA), or recombinant M. bovis pilin–cytotoxin carboxy terminus + ISCOM matrix (pilin–MbxA); calves received secondary vaccinations 21 days later. Calves were examined once weekly for 18 weeks for the development of corneal ulcers associated with IBK. Overall, the pilin–MbxA vaccinated group had the lowest overall cumulative proportion of ulcerated calves. Calves that received MbxA, whether alone or with pilin had significantly higher M. bovis cytotoxin serum neutralizing titers as compared to control calves. Results of ocular cultures suggested that vaccination with an M. bovis antigen affected organism type isolated from an ulcer: M. bovis was cultured more often from the eyes of control calves than from the eyes of calves vaccinated with MbxA and pilin–MbxA. In addition, vaccination of calves with MbxA and pilin–MbxA resulted in a higher prevalence of Moraxella bovoculi sp. nov. in ocular cultures. While no significant difference was observed between a cytotoxin versus pilin + cytotoxin vaccine against IBK, the reduced cumulative proportion of IBK in the pilin–cytotoxin vaccinated calves suggests it may provide an advantage over a cytotoxin vaccine alone. Efficacy of an M. bovis vaccine may be reduced in herds where IBK is associated with M. bovoculi sp. nov.
-
prevention of naturally occurring infectious bovine keratoconjunctivitis with a recombinant moraxella bovis pilin moraxella bovis cytotoxin ISCOM matrix adjuvanted vaccine
Veterinary Microbiology, 2007Co-Authors: John A. Angelos, Robert G Bonifacio, Louise M. Ball, John F HessAbstract:Abstract To evaluate the efficacy of a recombinant Moraxella bovis pilin– M. bovis cytotoxin subunit vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis (IBK; pinkeye), a randomized, blinded, controlled field trial was conducted during summer 2005 in a northern California herd of beef cattle. One hundred and one steers were vaccinated with ISCOM matrix (adjuvant control), recombinant M. bovis cytotoxin carboxy terminus + ISCOM matrix (MbxA), or recombinant M. bovis pilin–cytotoxin carboxy terminus + ISCOM matrix (pilin–MbxA); calves received secondary vaccinations 21 days later. Calves were examined once weekly for 18 weeks for the development of corneal ulcers associated with IBK. Overall, the pilin–MbxA vaccinated group had the lowest overall cumulative proportion of ulcerated calves. Calves that received MbxA, whether alone or with pilin had significantly higher M. bovis cytotoxin serum neutralizing titers as compared to control calves. Results of ocular cultures suggested that vaccination with an M. bovis antigen affected organism type isolated from an ulcer: M. bovis was cultured more often from the eyes of control calves than from the eyes of calves vaccinated with MbxA and pilin–MbxA. In addition, vaccination of calves with MbxA and pilin–MbxA resulted in a higher prevalence of Moraxella bovoculi sp. nov. in ocular cultures. While no significant difference was observed between a cytotoxin versus pilin + cytotoxin vaccine against IBK, the reduced cumulative proportion of IBK in the pilin–cytotoxin vaccinated calves suggests it may provide an advantage over a cytotoxin vaccine alone. Efficacy of an M. bovis vaccine may be reduced in herds where IBK is associated with M. bovoculi sp. nov.
-
prevention of naturally occurring infectious bovine keratoconjunctivitis with a recombinant moraxella bovis cytotoxin ISCOM matrix adjuvanted vaccine
Vaccine, 2004Co-Authors: John A. Angelos, John F Hess, L. W. GeorgeAbstract:The efficacy of a recombinant Moraxella bovis cytotoxin subunit vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis (IBK) was evaluated in a randomized, blinded, controlled field trial. Ninety-three cross bred beef calves were vaccinated with either saline, ISCOM matrix (adjuvant control), or a recombinant M. bovis cytotoxin carboxy terminus peptide plus ISCOM matrix and boostered 21 days later. Ocular examinations were performed once weekly for 20 weeks. At week 12, the cumulative proportion of calves with ulcerated eyes in the recombinant vaccine group was significantly lower than in the saline control group. Throughout the 20 week trial, the cumulative proportion of ulcerated calves remained lowest in the recombinant vaccine group. By week 7, nonulcerated calves in the recombinant vaccine group had significantly higher changes in serum neutralizing titers and cytotoxin specific to total IgG ratios in serum and tears as compared to calves in the control groups. The trend for a reduced cumulative proportion of IBK in the vaccinated calves over the 20 week trial suggests that a recombinant M. bovis cytotoxin vaccine may be beneficial in helping to prevent naturally occurring IBK.
John A. Angelos - One of the best experts on this subject based on the ideXlab platform.
-
randomized controlled field trial to assess efficacy of a moraxella bovis pilin cytotoxin moraxella bovoculi cytotoxin subunit vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis
American Journal of Veterinary Research, 2012Co-Authors: John A. Angelos, Louise M. Ball, Khaled G Gohary, John F HessAbstract:Objective—To evaluate efficacy of a recombinant Moraxella bovis pilin-cytotoxin-Moraxella bovoculi cytotoxin subunit vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis (IBK). Animals—107 beef steers. Procedures—2 groups of calves were inoculated SC with an immunostimulating complex (ISCOM) matrix adjuvant (control group; n = 54) or a recombinant M bovis pilin-cytotoxin–M bovoculi cytotoxin subunit antigen with the ISCOM matrix adjuvant (vaccine group; 53); calves received booster injections 21 days later. Calves were examined once weekly for 16 weeks. Investigators and herd managers were not aware of the inoculum administered to each calf throughout the trial. Primary outcome of interest was the cumulative proportion of calves that developed IBK. Serum samples were obtained before inoculation (day 0) and on days 42 and 112. Serum hemolysin-neutralizing titers against native M bovis and M bovoculi cytotoxin were determined. Results—No difference was detected between groups for th...
-
prevention of naturally occurring infectious bovine keratoconjunctivitis with a recombinant moraxella bovis pilin moraxella bovis cytotoxin ISCOM matrix adjuvanted vaccine
Veterinary Microbiology, 2007Co-Authors: John A. Angelos, Robert G Bonifacio, Louise M. Ball, John F HessAbstract:Abstract To evaluate the efficacy of a recombinant Moraxella bovis pilin– M. bovis cytotoxin subunit vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis (IBK; pinkeye), a randomized, blinded, controlled field trial was conducted during summer 2005 in a northern California herd of beef cattle. One hundred and one steers were vaccinated with ISCOM matrix (adjuvant control), recombinant M. bovis cytotoxin carboxy terminus + ISCOM matrix (MbxA), or recombinant M. bovis pilin–cytotoxin carboxy terminus + ISCOM matrix (pilin–MbxA); calves received secondary vaccinations 21 days later. Calves were examined once weekly for 18 weeks for the development of corneal ulcers associated with IBK. Overall, the pilin–MbxA vaccinated group had the lowest overall cumulative proportion of ulcerated calves. Calves that received MbxA, whether alone or with pilin had significantly higher M. bovis cytotoxin serum neutralizing titers as compared to control calves. Results of ocular cultures suggested that vaccination with an M. bovis antigen affected organism type isolated from an ulcer: M. bovis was cultured more often from the eyes of control calves than from the eyes of calves vaccinated with MbxA and pilin–MbxA. In addition, vaccination of calves with MbxA and pilin–MbxA resulted in a higher prevalence of Moraxella bovoculi sp. nov. in ocular cultures. While no significant difference was observed between a cytotoxin versus pilin + cytotoxin vaccine against IBK, the reduced cumulative proportion of IBK in the pilin–cytotoxin vaccinated calves suggests it may provide an advantage over a cytotoxin vaccine alone. Efficacy of an M. bovis vaccine may be reduced in herds where IBK is associated with M. bovoculi sp. nov.
-
prevention of naturally occurring infectious bovine keratoconjunctivitis with a recombinant moraxella bovis pilin moraxella bovis cytotoxin ISCOM matrix adjuvanted vaccine
Veterinary Microbiology, 2007Co-Authors: John A. Angelos, Robert G Bonifacio, Louise M. Ball, John F HessAbstract:Abstract To evaluate the efficacy of a recombinant Moraxella bovis pilin– M. bovis cytotoxin subunit vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis (IBK; pinkeye), a randomized, blinded, controlled field trial was conducted during summer 2005 in a northern California herd of beef cattle. One hundred and one steers were vaccinated with ISCOM matrix (adjuvant control), recombinant M. bovis cytotoxin carboxy terminus + ISCOM matrix (MbxA), or recombinant M. bovis pilin–cytotoxin carboxy terminus + ISCOM matrix (pilin–MbxA); calves received secondary vaccinations 21 days later. Calves were examined once weekly for 18 weeks for the development of corneal ulcers associated with IBK. Overall, the pilin–MbxA vaccinated group had the lowest overall cumulative proportion of ulcerated calves. Calves that received MbxA, whether alone or with pilin had significantly higher M. bovis cytotoxin serum neutralizing titers as compared to control calves. Results of ocular cultures suggested that vaccination with an M. bovis antigen affected organism type isolated from an ulcer: M. bovis was cultured more often from the eyes of control calves than from the eyes of calves vaccinated with MbxA and pilin–MbxA. In addition, vaccination of calves with MbxA and pilin–MbxA resulted in a higher prevalence of Moraxella bovoculi sp. nov. in ocular cultures. While no significant difference was observed between a cytotoxin versus pilin + cytotoxin vaccine against IBK, the reduced cumulative proportion of IBK in the pilin–cytotoxin vaccinated calves suggests it may provide an advantage over a cytotoxin vaccine alone. Efficacy of an M. bovis vaccine may be reduced in herds where IBK is associated with M. bovoculi sp. nov.
-
prevention of naturally occurring infectious bovine keratoconjunctivitis with a recombinant moraxella bovis cytotoxin ISCOM matrix adjuvanted vaccine
Vaccine, 2004Co-Authors: John A. Angelos, John F Hess, L. W. GeorgeAbstract:The efficacy of a recombinant Moraxella bovis cytotoxin subunit vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis (IBK) was evaluated in a randomized, blinded, controlled field trial. Ninety-three cross bred beef calves were vaccinated with either saline, ISCOM matrix (adjuvant control), or a recombinant M. bovis cytotoxin carboxy terminus peptide plus ISCOM matrix and boostered 21 days later. Ocular examinations were performed once weekly for 20 weeks. At week 12, the cumulative proportion of calves with ulcerated eyes in the recombinant vaccine group was significantly lower than in the saline control group. Throughout the 20 week trial, the cumulative proportion of ulcerated calves remained lowest in the recombinant vaccine group. By week 7, nonulcerated calves in the recombinant vaccine group had significantly higher changes in serum neutralizing titers and cytotoxin specific to total IgG ratios in serum and tears as compared to calves in the control groups. The trend for a reduced cumulative proportion of IBK in the vaccinated calves over the 20 week trial suggests that a recombinant M. bovis cytotoxin vaccine may be beneficial in helping to prevent naturally occurring IBK.
Bror Morein - One of the best experts on this subject based on the ideXlab platform.
-
ISCOM technology based matrix m adjuvant success in future vaccines relies on formulation
Expert Review of Vaccines, 2011Co-Authors: Karin Lovgren Bengtsson, Bror Morein, Albert D M E OsterhausAbstract:ISCOM technology-based Matrix M (TM) adjuvant : success in future vaccines relies on formulation
-
the immunomodulating properties of human respiratory syncytial virus and immunostimulating complexes containing quillaja saponin components qh a qh c and iscoprep703
Fems Immunology and Medical Microbiology, 2005Co-Authors: Matthias Regner, Claireanne Siegrist, Paul Lambert, Margaret Chen, Karin La Vgren Bengtsson, Bror MoreinAbstract:A successful vaccine against human RSV (HRSV) is likely to induce a Th1 or a balanced Th1/TH2 cytokine response. We tested a panel of HRSV immunostimulating complexes (ISCOMs) containing different Quillaja saponin fractions (QH-A, QH-C, and 703: a mixture of 70% QH-A and 30% QH-C) with different immunological properties for their capacity of inducing innate and acquired immune responses. The HRSV 703 ISCOMs induced the strongest innate and acquired immune responses, followed by RSV QH-C and QH-A ISCOMs. All three formulations induced various degrees of Th1 bias response with prominent production of IFN-γ being 10–50 times higher than that of IL-4 and IL-5. The HRSV specific IgG isotype profile correlated with the predominant secretion of Th1 cytokines, with strong induction of IgG2a antibodies. The 703 ISCOMs induced the most pronounced Th1 profile followed by QH-C and QH-A ISCOMs. The high incorporation of F protein in these ISCOMs compared to G protein combined with the Th1 biased nature of ISCOM are likely to be the causes to promote a Th1 type of profile. The prospect to formulate an RSV ISCOM formulation with an optimal Th1/Th2 balance is in reach particularly in view of the versatile properties of the ISCOM concept.
-
experimental field trial with an immunostimulating complex ISCOM vaccine against contagious bovine pleuropneumonia
Journal of Veterinary Medicine Series B-infectious Diseases and Veterinary Public Health, 2003Co-Authors: O J B Hubschle, Izzeldin Abusugra, Georgina Tjipurazaire, G Di Francesca, F Mettler, A Pini, Bror MoreinAbstract:: The experimental field trial with an immunostimulating complex (ISCOM) vaccine has been an occasion to explore the role of a Th1 response in the pathogenesis caused by Mycoplasma mycoides subsp. mycoides small colony (MmmSC) and in immune protection. The ISCOM complex is known to promote Th1 response. Antibodies to MmmSC were detected by indirect enzyme-linked immunosorbent assay (ELISA) in the vaccinated cattle, although the levels were lower than in a previous study. No antibodies were detected by complement fixation test (CF). After the challenge infection, vaccinated animals developed CF antibody response. They showed significantly reduced mortality compared with controls. However, gross pathological and histopathological score for vaccinated animals was as high as for the non-vaccinated, characterized by a high inflammatory reaction with histopathology dominated by interlobular pneumonia with vasculitis.
-
systemic and intestinal antibody secreting cell responses and protection in gnotobiotic pigs immunized orally with attenuated wa human rotavirus and wa 2 6 rotavirus like particles associated with immunostimulating complexes
Vaccine, 2002Co-Authors: Cristiana Iosef, Karin Lovgren Bengtsson, Bror Morein, Marli S P Azevedo, Lijuan Yuan, Kwangil Jeong, Trang Van Nguyen, Kyeongok Chang, Yunjeong Kim, P R NielsenAbstract:The undesirable side effects and variable efficacy of some oral live rotavirus vaccines in infants have necessitated alternative vaccine approaches. We evaluated a recombinant RFVP2/WaVP6 rotavirus-like-particle (2/6VLP) oral vaccine, using an immunostimulating complex (ISCOM) matrix as adjuvant, in a gnotobiotic (Gn) pig model of human rotavirus (HRV) disease. The 2/6VLPs adhered to the ISCOM-matrix (2/6VLP-ISCOM ) and were antigenic, but they failed to induce protection. However, when combined with attenuated (Att) HRV for oral priming, the 2/6VLP-ISCOM vaccine was effective as a booster and induced partial protection against virulent Wa HRV. The 250 microg 2/6VLP dose was more effective than 100 microg. The highest mean numbers of IgA antibody secreting cells evaluated by ELISPOT in intestinal lymphoid tissues were in pigs receiving AttHRV+2/6VLP-ISCOM or three doses of AttHRV and were associated with the highest protection rates.
-
internalization of ISCOM borne antigens and presentation under mhc class i or class ii restriction
Cellular Immunology, 1998Co-Authors: M C Villacres, Shahriar Behboudi, T Nikkila, Karin Lovgrenbengtsson, Bror MoreinAbstract:Exogenous nonreplicating antigens (Ag) incorporated into into immunostimulating complexes (ISCOMs) induce CTE responses under MHC class I restriction. A requirement for inducing CTL responses is that the Ag is delivered to the cytosol of antigen-presenting cells (APC), a route restricted to endogenously produced Ag. To investigate the mechanisms by which ISCOMs elicit MHC class I-restricted responses, the intracellular distribution of influenza virus envelope proteins incorporated in ISCOMs (flu-ISCOMs) or in micelles (flu-micelles) was studied in vitro using murine peritoneal cells (PEC). Ultrathin sections of cells pulsed with biotinylated flu-ISCOMs or flu-micelles were analyzed by electron microscopy after detection of the biotin label by reaction with streptavidin-gold. PEC pulsed with flu-ISCOMs showed a pattern of scattered gold particles distributed in clear and dense vesicles as well as in the intracellular space but not associated with. organelles. In cells pulsed with flu-micelles, Ag was also detected in most cellular compartments but at a considerably lower concentration. The intracellular distribution of particulate Ag in ISCOM or micelle form was confirmed by lysis and differential centrifugation of Ag-pulsed APC. Furthermore, P815 cells pulsed with flu-ISCOMs were lysed by specific immune effecters showing that time ISCOM-AE; was processed and presented by class I-expressing APC. flu-ISCOMs were internalized about 50-fold more efficiently than ovalbumin ISCOMs (ova-ISCOMs) suggesting that the nature of the protein and/or the presence of cellular receptors are important factors influencing the capacity of APC to take up ISCOM-borne proteins. PEC accounted for the most active internalization of ISCOM-borne Ag, although splenic dendritic cells and B cells also took up flu-ISCOMs with remarkable efficiency. (C) 1998 Academic Press.
Louise M. Ball - One of the best experts on this subject based on the ideXlab platform.
-
randomized controlled field trial to assess efficacy of a moraxella bovis pilin cytotoxin moraxella bovoculi cytotoxin subunit vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis
American Journal of Veterinary Research, 2012Co-Authors: John A. Angelos, Louise M. Ball, Khaled G Gohary, John F HessAbstract:Objective—To evaluate efficacy of a recombinant Moraxella bovis pilin-cytotoxin-Moraxella bovoculi cytotoxin subunit vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis (IBK). Animals—107 beef steers. Procedures—2 groups of calves were inoculated SC with an immunostimulating complex (ISCOM) matrix adjuvant (control group; n = 54) or a recombinant M bovis pilin-cytotoxin–M bovoculi cytotoxin subunit antigen with the ISCOM matrix adjuvant (vaccine group; 53); calves received booster injections 21 days later. Calves were examined once weekly for 16 weeks. Investigators and herd managers were not aware of the inoculum administered to each calf throughout the trial. Primary outcome of interest was the cumulative proportion of calves that developed IBK. Serum samples were obtained before inoculation (day 0) and on days 42 and 112. Serum hemolysin-neutralizing titers against native M bovis and M bovoculi cytotoxin were determined. Results—No difference was detected between groups for th...
-
prevention of naturally occurring infectious bovine keratoconjunctivitis with a recombinant moraxella bovis pilin moraxella bovis cytotoxin ISCOM matrix adjuvanted vaccine
Veterinary Microbiology, 2007Co-Authors: John A. Angelos, Robert G Bonifacio, Louise M. Ball, John F HessAbstract:Abstract To evaluate the efficacy of a recombinant Moraxella bovis pilin– M. bovis cytotoxin subunit vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis (IBK; pinkeye), a randomized, blinded, controlled field trial was conducted during summer 2005 in a northern California herd of beef cattle. One hundred and one steers were vaccinated with ISCOM matrix (adjuvant control), recombinant M. bovis cytotoxin carboxy terminus + ISCOM matrix (MbxA), or recombinant M. bovis pilin–cytotoxin carboxy terminus + ISCOM matrix (pilin–MbxA); calves received secondary vaccinations 21 days later. Calves were examined once weekly for 18 weeks for the development of corneal ulcers associated with IBK. Overall, the pilin–MbxA vaccinated group had the lowest overall cumulative proportion of ulcerated calves. Calves that received MbxA, whether alone or with pilin had significantly higher M. bovis cytotoxin serum neutralizing titers as compared to control calves. Results of ocular cultures suggested that vaccination with an M. bovis antigen affected organism type isolated from an ulcer: M. bovis was cultured more often from the eyes of control calves than from the eyes of calves vaccinated with MbxA and pilin–MbxA. In addition, vaccination of calves with MbxA and pilin–MbxA resulted in a higher prevalence of Moraxella bovoculi sp. nov. in ocular cultures. While no significant difference was observed between a cytotoxin versus pilin + cytotoxin vaccine against IBK, the reduced cumulative proportion of IBK in the pilin–cytotoxin vaccinated calves suggests it may provide an advantage over a cytotoxin vaccine alone. Efficacy of an M. bovis vaccine may be reduced in herds where IBK is associated with M. bovoculi sp. nov.
-
prevention of naturally occurring infectious bovine keratoconjunctivitis with a recombinant moraxella bovis pilin moraxella bovis cytotoxin ISCOM matrix adjuvanted vaccine
Veterinary Microbiology, 2007Co-Authors: John A. Angelos, Robert G Bonifacio, Louise M. Ball, John F HessAbstract:Abstract To evaluate the efficacy of a recombinant Moraxella bovis pilin– M. bovis cytotoxin subunit vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis (IBK; pinkeye), a randomized, blinded, controlled field trial was conducted during summer 2005 in a northern California herd of beef cattle. One hundred and one steers were vaccinated with ISCOM matrix (adjuvant control), recombinant M. bovis cytotoxin carboxy terminus + ISCOM matrix (MbxA), or recombinant M. bovis pilin–cytotoxin carboxy terminus + ISCOM matrix (pilin–MbxA); calves received secondary vaccinations 21 days later. Calves were examined once weekly for 18 weeks for the development of corneal ulcers associated with IBK. Overall, the pilin–MbxA vaccinated group had the lowest overall cumulative proportion of ulcerated calves. Calves that received MbxA, whether alone or with pilin had significantly higher M. bovis cytotoxin serum neutralizing titers as compared to control calves. Results of ocular cultures suggested that vaccination with an M. bovis antigen affected organism type isolated from an ulcer: M. bovis was cultured more often from the eyes of control calves than from the eyes of calves vaccinated with MbxA and pilin–MbxA. In addition, vaccination of calves with MbxA and pilin–MbxA resulted in a higher prevalence of Moraxella bovoculi sp. nov. in ocular cultures. While no significant difference was observed between a cytotoxin versus pilin + cytotoxin vaccine against IBK, the reduced cumulative proportion of IBK in the pilin–cytotoxin vaccinated calves suggests it may provide an advantage over a cytotoxin vaccine alone. Efficacy of an M. bovis vaccine may be reduced in herds where IBK is associated with M. bovoculi sp. nov.
Robert G Bonifacio - One of the best experts on this subject based on the ideXlab platform.
-
prevention of naturally occurring infectious bovine keratoconjunctivitis with a recombinant moraxella bovis pilin moraxella bovis cytotoxin ISCOM matrix adjuvanted vaccine
Veterinary Microbiology, 2007Co-Authors: John A. Angelos, Robert G Bonifacio, Louise M. Ball, John F HessAbstract:Abstract To evaluate the efficacy of a recombinant Moraxella bovis pilin– M. bovis cytotoxin subunit vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis (IBK; pinkeye), a randomized, blinded, controlled field trial was conducted during summer 2005 in a northern California herd of beef cattle. One hundred and one steers were vaccinated with ISCOM matrix (adjuvant control), recombinant M. bovis cytotoxin carboxy terminus + ISCOM matrix (MbxA), or recombinant M. bovis pilin–cytotoxin carboxy terminus + ISCOM matrix (pilin–MbxA); calves received secondary vaccinations 21 days later. Calves were examined once weekly for 18 weeks for the development of corneal ulcers associated with IBK. Overall, the pilin–MbxA vaccinated group had the lowest overall cumulative proportion of ulcerated calves. Calves that received MbxA, whether alone or with pilin had significantly higher M. bovis cytotoxin serum neutralizing titers as compared to control calves. Results of ocular cultures suggested that vaccination with an M. bovis antigen affected organism type isolated from an ulcer: M. bovis was cultured more often from the eyes of control calves than from the eyes of calves vaccinated with MbxA and pilin–MbxA. In addition, vaccination of calves with MbxA and pilin–MbxA resulted in a higher prevalence of Moraxella bovoculi sp. nov. in ocular cultures. While no significant difference was observed between a cytotoxin versus pilin + cytotoxin vaccine against IBK, the reduced cumulative proportion of IBK in the pilin–cytotoxin vaccinated calves suggests it may provide an advantage over a cytotoxin vaccine alone. Efficacy of an M. bovis vaccine may be reduced in herds where IBK is associated with M. bovoculi sp. nov.
-
prevention of naturally occurring infectious bovine keratoconjunctivitis with a recombinant moraxella bovis pilin moraxella bovis cytotoxin ISCOM matrix adjuvanted vaccine
Veterinary Microbiology, 2007Co-Authors: John A. Angelos, Robert G Bonifacio, Louise M. Ball, John F HessAbstract:Abstract To evaluate the efficacy of a recombinant Moraxella bovis pilin– M. bovis cytotoxin subunit vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis (IBK; pinkeye), a randomized, blinded, controlled field trial was conducted during summer 2005 in a northern California herd of beef cattle. One hundred and one steers were vaccinated with ISCOM matrix (adjuvant control), recombinant M. bovis cytotoxin carboxy terminus + ISCOM matrix (MbxA), or recombinant M. bovis pilin–cytotoxin carboxy terminus + ISCOM matrix (pilin–MbxA); calves received secondary vaccinations 21 days later. Calves were examined once weekly for 18 weeks for the development of corneal ulcers associated with IBK. Overall, the pilin–MbxA vaccinated group had the lowest overall cumulative proportion of ulcerated calves. Calves that received MbxA, whether alone or with pilin had significantly higher M. bovis cytotoxin serum neutralizing titers as compared to control calves. Results of ocular cultures suggested that vaccination with an M. bovis antigen affected organism type isolated from an ulcer: M. bovis was cultured more often from the eyes of control calves than from the eyes of calves vaccinated with MbxA and pilin–MbxA. In addition, vaccination of calves with MbxA and pilin–MbxA resulted in a higher prevalence of Moraxella bovoculi sp. nov. in ocular cultures. While no significant difference was observed between a cytotoxin versus pilin + cytotoxin vaccine against IBK, the reduced cumulative proportion of IBK in the pilin–cytotoxin vaccinated calves suggests it may provide an advantage over a cytotoxin vaccine alone. Efficacy of an M. bovis vaccine may be reduced in herds where IBK is associated with M. bovoculi sp. nov.
